JP2014522847A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014522847A5 JP2014522847A5 JP2014519190A JP2014519190A JP2014522847A5 JP 2014522847 A5 JP2014522847 A5 JP 2014522847A5 JP 2014519190 A JP2014519190 A JP 2014519190A JP 2014519190 A JP2014519190 A JP 2014519190A JP 2014522847 A5 JP2014522847 A5 JP 2014522847A5
- Authority
- JP
- Japan
- Prior art keywords
- dihydrobenzo
- phenyl
- alkyl
- oxazepin
- trifluoromethoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims description 371
- 125000001072 heteroaryl group Chemical group 0.000 claims description 361
- -1 4-cyclopropoxy, 4-cyclobutylmethoxy Chemical group 0.000 claims description 356
- 125000003118 aryl group Chemical group 0.000 claims description 329
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 315
- 125000000623 heterocyclic group Chemical group 0.000 claims description 315
- 125000005843 halogen group Chemical group 0.000 claims description 199
- 125000001424 substituent group Chemical group 0.000 claims description 189
- NBJDSMIOWPVWRW-UHFFFAOYSA-N 2h-oxazepin-5-one Chemical compound O=C1C=CNOC=C1 NBJDSMIOWPVWRW-UHFFFAOYSA-N 0.000 claims description 154
- 229910052739 hydrogen Inorganic materials 0.000 claims description 82
- 239000001257 hydrogen Substances 0.000 claims description 82
- 150000001875 compounds Chemical class 0.000 claims description 78
- 150000002431 hydrogen Chemical class 0.000 claims description 72
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 69
- 125000003545 alkoxy group Chemical group 0.000 claims description 66
- 125000000304 alkynyl group Chemical group 0.000 claims description 66
- 239000000203 mixture Substances 0.000 claims description 49
- 229910052799 carbon Inorganic materials 0.000 claims description 47
- 150000003839 salts Chemical class 0.000 claims description 47
- 125000003342 alkenyl group Chemical group 0.000 claims description 46
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 43
- 150000002148 esters Chemical class 0.000 claims description 43
- 125000004442 acylamino group Chemical group 0.000 claims description 42
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 38
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 38
- 125000004043 oxo group Chemical group O=* 0.000 claims description 37
- 229910052757 nitrogen Inorganic materials 0.000 claims description 27
- 125000002102 aryl alkyloxo group Chemical group 0.000 claims description 21
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 21
- KCUHSGJIUSNWHG-UHFFFAOYSA-N 2,3-dihydrooxazepin-6-one Chemical compound O1NCC=CC(C1)=O KCUHSGJIUSNWHG-UHFFFAOYSA-N 0.000 claims description 20
- 125000004104 aryloxy group Chemical group 0.000 claims description 20
- 125000006514 pyridin-2-ylmethyl group Chemical group [H]C1=C([H])C([H])=C([H])C(=N1)C([H])([H])* 0.000 claims description 19
- 125000002947 alkylene group Chemical group 0.000 claims description 17
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims description 16
- 229910052805 deuterium Inorganic materials 0.000 claims description 16
- YNUAEEJQYHYLMS-UHFFFAOYSA-N 4-(pyrimidin-2-ylmethyl)-7-[4-(trifluoromethoxy)phenyl]-2,3-dihydro-1,4-benzoxazepin-5-one Chemical compound C1=CC(OC(F)(F)F)=CC=C1C1=CC=C(OCCN(CC=2N=CC=CN=2)C2=O)C2=C1 YNUAEEJQYHYLMS-UHFFFAOYSA-N 0.000 claims description 10
- WXLCDTBTIVJDCE-UHFFFAOYSA-N 1,4-oxazepine Chemical compound O1C=CC=NC=C1 WXLCDTBTIVJDCE-UHFFFAOYSA-N 0.000 claims description 9
- 206010007559 Cardiac failure congestive Diseases 0.000 claims description 8
- 201000010099 disease Diseases 0.000 claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- 206010002383 Angina Pectoris Diseases 0.000 claims description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 6
- 125000004778 2,2-difluoroethyl group Chemical group [H]C([H])(*)C([H])(F)F 0.000 claims description 5
- 206010019280 Heart failures Diseases 0.000 claims description 5
- MTZQAGJQAFMTAQ-UHFFFAOYSA-N ethyl benzoate Chemical compound CCOC(=O)C1=CC=CC=C1 MTZQAGJQAFMTAQ-UHFFFAOYSA-N 0.000 claims description 5
- 208000028867 ischemia Diseases 0.000 claims description 5
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 claims description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 4
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 4
- RPXNJCVSRBNJHA-UHFFFAOYSA-N n-[2-[5-oxo-7-[4-(trifluoromethoxy)phenyl]-2,3-dihydro-1,4-benzoxazepin-4-yl]ethyl]pyrimidine-2-carboxamide Chemical compound C1=CC(OC(F)(F)F)=CC=C1C1=CC=C(OCCN(CCNC(=O)C=2N=CC=CN=2)C2=O)C2=C1 RPXNJCVSRBNJHA-UHFFFAOYSA-N 0.000 claims description 4
- 125000004793 2,2,2-trifluoroethoxy group Chemical group FC(CO*)(F)F 0.000 claims description 3
- CPHXLFKIUVVIOQ-UHFFFAOYSA-N 2-(trifluoromethoxy)benzaldehyde Chemical group FC(F)(F)OC1=CC=CC=C1C=O CPHXLFKIUVVIOQ-UHFFFAOYSA-N 0.000 claims description 3
- XOFKKGMAEWHODX-UHFFFAOYSA-N 4-(pyrimidin-2-ylmethyl)-7-[4-(trifluoromethyl)phenyl]-2,3-dihydro-1,4-benzoxazepin-5-one Chemical compound C1=CC(C(F)(F)F)=CC=C1C1=CC=C(OCCN(CC=2N=CC=CN=2)C2=O)C2=C1 XOFKKGMAEWHODX-UHFFFAOYSA-N 0.000 claims description 3
- 208000004476 Acute Coronary Syndrome Diseases 0.000 claims description 3
- 206010003130 Arrhythmia supraventricular Diseases 0.000 claims description 3
- 206010007556 Cardiac failure acute Diseases 0.000 claims description 3
- 208000003037 Diastolic Heart Failure Diseases 0.000 claims description 3
- 206010022562 Intermittent claudication Diseases 0.000 claims description 3
- 208000005764 Peripheral Arterial Disease Diseases 0.000 claims description 3
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 claims description 3
- 206010063837 Reperfusion injury Diseases 0.000 claims description 3
- 208000007718 Stable Angina Diseases 0.000 claims description 3
- 208000008253 Systolic Heart Failure Diseases 0.000 claims description 3
- 206010047281 Ventricular arrhythmia Diseases 0.000 claims description 3
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 claims description 3
- 208000021156 intermittent vascular claudication Diseases 0.000 claims description 3
- 208000010125 myocardial infarction Diseases 0.000 claims description 3
- 208000002815 pulmonary hypertension Diseases 0.000 claims description 3
- 230000000306 recurrent effect Effects 0.000 claims description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 3
- QDKWLJJOYIFEBS-UHFFFAOYSA-N 1-fluoro-4-$l^{1}-oxidanylbenzene Chemical group [O]C1=CC=C(F)C=C1 QDKWLJJOYIFEBS-UHFFFAOYSA-N 0.000 claims description 2
- 125000006508 2,6-difluorobenzyl group Chemical group [H]C1=C([H])C(F)=C(C(F)=C1[H])C([H])([H])* 0.000 claims description 2
- NEURYOYRKPFLKH-UHFFFAOYSA-N 2-chloro-1-isocyanato-4-(trifluoromethyl)benzene Chemical group FC(F)(F)C1=CC=C(N=C=O)C(Cl)=C1 NEURYOYRKPFLKH-UHFFFAOYSA-N 0.000 claims description 2
- 125000006282 2-chlorobenzyl group Chemical group [H]C1=C([H])C(Cl)=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 2
- 125000004847 2-fluorobenzyl group Chemical group [H]C1=C([H])C(F)=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 2
- 125000006509 3,4-difluorobenzyl group Chemical group [H]C1=C(F)C(F)=C([H])C(=C1[H])C([H])([H])* 0.000 claims description 2
- 125000004860 4-ethylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 125000004176 4-fluorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1F)C([H])([H])* 0.000 claims description 2
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims description 2
- 125000004861 4-isopropyl phenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 2
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 2
- 208000019695 Migraine disease Diseases 0.000 claims description 2
- 206010033799 Paralysis Diseases 0.000 claims description 2
- 208000007814 Unstable Angina Diseases 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 230000003111 delayed effect Effects 0.000 claims description 2
- 206010012601 diabetes mellitus Diseases 0.000 claims description 2
- 206010015037 epilepsy Diseases 0.000 claims description 2
- 206010027599 migraine Diseases 0.000 claims description 2
- 208000004296 neuralgia Diseases 0.000 claims description 2
- 208000021722 neuropathic pain Diseases 0.000 claims description 2
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 229910052708 sodium Inorganic materials 0.000 claims description 2
- 239000011734 sodium Substances 0.000 claims description 2
- MSMUGKYVPPWLNZ-UHFFFAOYSA-N 1-[4-[5-oxo-4-(pyrimidin-2-ylmethyl)-2,3-dihydro-1,4-benzoxazepin-7-yl]phenyl]cyclopentane-1-carbonitrile Chemical compound C1COC2=CC=C(C=3C=CC(=CC=3)C3(CCCC3)C#N)C=C2C(=O)N1CC1=NC=CC=N1 MSMUGKYVPPWLNZ-UHFFFAOYSA-N 0.000 claims 2
- 150000001408 amides Chemical class 0.000 claims 2
- 125000001188 haloalkyl group Chemical group 0.000 claims 2
- VCLXRLYZVCWRIV-UHFFFAOYSA-N n-[2-[5-oxo-7-[4-(trifluoromethoxy)phenyl]-2,3-dihydro-1,4-benzoxazepin-4-yl]ethyl]cyclopropanesulfonamide Chemical compound C1=CC(OC(F)(F)F)=CC=C1C1=CC=C(OCCN(CCNS(=O)(=O)C2CC2)C2=O)C2=C1 VCLXRLYZVCWRIV-UHFFFAOYSA-N 0.000 claims 2
- DROIHSMGGKKIJT-UHFFFAOYSA-N propane-1-sulfonamide Chemical compound CCCS(N)(=O)=O DROIHSMGGKKIJT-UHFFFAOYSA-N 0.000 claims 2
- JXNDSKLORQDUHC-UHFFFAOYSA-N 6-[[5-oxo-7-[4-(trifluoromethoxy)phenyl]-2,3-dihydro-1,4-benzoxazepin-4-yl]methyl]pyridine-2-carbonitrile Chemical compound C1=CC(OC(F)(F)F)=CC=C1C1=CC=C(OCCN(CC=2N=C(C=CC=2)C#N)C2=O)C2=C1 JXNDSKLORQDUHC-UHFFFAOYSA-N 0.000 claims 1
- VOTBLROURANVRM-UHFFFAOYSA-N 7-[3-fluoro-4-(trifluoromethyl)phenyl]-4-(pyrimidin-2-ylmethyl)-2,3-dihydro-1,4-benzoxazepin-5-one Chemical compound C1=C(C(F)(F)F)C(F)=CC(C=2C=C3C(=O)N(CC=4N=CC=CN=4)CCOC3=CC=2)=C1 VOTBLROURANVRM-UHFFFAOYSA-N 0.000 claims 1
- 206010002388 Angina unstable Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 1
- 201000004332 intermediate coronary syndrome Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- GRJHONXDTNBDTC-UHFFFAOYSA-N phenyl trifluoromethanesulfonate Chemical compound FC(F)(F)S(=O)(=O)OC1=CC=CC=C1 GRJHONXDTNBDTC-UHFFFAOYSA-N 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 42
- QHXILXDHCYOAQA-UHFFFAOYSA-N 2h-1,4-oxazepin-5-one Chemical compound O=C1C=COCC=N1 QHXILXDHCYOAQA-UHFFFAOYSA-N 0.000 description 31
- 125000004965 chloroalkyl group Chemical group 0.000 description 18
- 125000006583 (C1-C3) haloalkyl group Chemical group 0.000 description 17
- 241000102542 Kara Species 0.000 description 14
- WSFSSNUMVMOOMR-BJUDXGSMSA-N methanone Chemical compound O=[11CH2] WSFSSNUMVMOOMR-BJUDXGSMSA-N 0.000 description 13
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 12
- 125000000392 cycloalkenyl group Chemical group 0.000 description 11
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 11
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 10
- 125000004429 atom Chemical group 0.000 description 10
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 7
- 238000000034 method Methods 0.000 description 6
- 150000001721 carbon Chemical group 0.000 description 5
- 125000005842 heteroatom Chemical group 0.000 description 5
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 4
- 125000004419 alkynylene group Chemical group 0.000 description 4
- 125000002757 morpholinyl group Chemical group 0.000 description 4
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 4
- 241000239366 Euphausiacea Species 0.000 description 3
- GLUUGHFHXGJENI-UHFFFAOYSA-N diethylenediamine Natural products C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 3
- PKVNVXXWANAAFP-UHFFFAOYSA-N 1,7-dihydro-1,4-diazepin-6-one Chemical compound O=C1CNC=CN=C1 PKVNVXXWANAAFP-UHFFFAOYSA-N 0.000 description 2
- GXQLLMGNQZULKS-UHFFFAOYSA-N 1-methyl-4-(2-phenylmethoxyethyl)-7-[4-(trifluoromethoxy)phenyl]-3h-1,4-benzodiazepine-2,5-dione Chemical compound C1C(=O)N(C)C2=CC=C(C=3C=CC(OC(F)(F)F)=CC=3)C=C2C(=O)N1CCOCC1=CC=CC=C1 GXQLLMGNQZULKS-UHFFFAOYSA-N 0.000 description 2
- LBHUBBRMFWBZLH-UHFFFAOYSA-N 4-benzyl-1-methyl-7-[4-(trifluoromethyl)phenyl]-3h-1,4-benzodiazepine-2,5-dione Chemical compound C1C(=O)N(C)C2=CC=C(C=3C=CC(=CC=3)C(F)(F)F)C=C2C(=O)N1CC1=CC=CC=C1 LBHUBBRMFWBZLH-UHFFFAOYSA-N 0.000 description 2
- RDQOUFQBZLSFIE-UHFFFAOYSA-N 4-benzyl-7-[4-(trifluoromethyl)phenyl]-1,3-dihydro-1,4-benzodiazepine-2,5-dione Chemical compound C1=CC(C(F)(F)F)=CC=C1C1=CC=C(NC(=O)CN(CC=2C=CC=CC=2)C2=O)C2=C1 RDQOUFQBZLSFIE-UHFFFAOYSA-N 0.000 description 2
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 2
- 102100025027 E3 ubiquitin-protein ligase TRIM69 Human genes 0.000 description 2
- 101000830203 Homo sapiens E3 ubiquitin-protein ligase TRIM69 Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical group C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- 125000004450 alkenylene group Chemical group 0.000 description 2
- 125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- SVPZJHKVRMRREG-UHFFFAOYSA-N cyclopentanecarbonitrile Chemical compound N#CC1CCCC1 SVPZJHKVRMRREG-UHFFFAOYSA-N 0.000 description 2
- 125000004785 fluoromethoxy group Chemical group [H]C([H])(F)O* 0.000 description 2
- 125000004193 piperazinyl group Chemical group 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 125000001305 1,2,4-triazol-3-yl group Chemical group [H]N1N=C([*])N=C1[H] 0.000 description 1
- 125000006432 1-methyl cyclopropyl group Chemical group [H]C([H])([H])C1(*)C([H])([H])C1([H])[H] 0.000 description 1
- MDWWPRNUHKMQCT-UHFFFAOYSA-N 2-cyclopropylthiophene Chemical group C1CC1C1=CC=CS1 MDWWPRNUHKMQCT-UHFFFAOYSA-N 0.000 description 1
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- FGKQHXRVPDLTDF-UHFFFAOYSA-N 3,4-dihydro-2h-1,4-benzoxazepin-5-one Chemical compound O=C1NCCOC2=CC=CC=C12 FGKQHXRVPDLTDF-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 101100037618 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) ant-1 gene Proteins 0.000 description 1
- 229910000752 Prince's Metal Inorganic materials 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 125000003037 imidazol-2-yl group Chemical group [H]N1C([*])=NC([H])=C1[H] 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
- 150000004885 piperazines Chemical class 0.000 description 1
- 125000004307 pyrazin-2-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 description 1
- 125000002206 pyridazin-3-yl group Chemical group [H]C1=C([H])C([H])=C(*)N=N1 0.000 description 1
- 125000005504 styryl group Chemical group 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000004495 thiazol-4-yl group Chemical group S1C=NC(=C1)* 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161503980P | 2011-07-01 | 2011-07-01 | |
| US61/503,980 | 2011-07-01 | ||
| US201161582160P | 2011-12-30 | 2011-12-30 | |
| US61/582,160 | 2011-12-30 | ||
| PCT/US2012/045086 WO2013006485A1 (en) | 2011-07-01 | 2012-06-29 | Fused benzoxazepinones as ion channel modulators |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015255906A Division JP6273250B2 (ja) | 2011-07-01 | 2015-12-28 | イオンチャネルモジュレーターとしての縮合複素環式化合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014522847A JP2014522847A (ja) | 2014-09-08 |
| JP2014522847A5 true JP2014522847A5 (enExample) | 2015-10-15 |
| JP5889407B2 JP5889407B2 (ja) | 2016-03-22 |
Family
ID=46513866
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014519190A Expired - Fee Related JP5889407B2 (ja) | 2011-07-01 | 2012-06-29 | イオンチャネルモジュレーターとしての縮合複素環式化合物 |
| JP2015255906A Expired - Fee Related JP6273250B2 (ja) | 2011-07-01 | 2015-12-28 | イオンチャネルモジュレーターとしての縮合複素環式化合物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015255906A Expired - Fee Related JP6273250B2 (ja) | 2011-07-01 | 2015-12-28 | イオンチャネルモジュレーターとしての縮合複素環式化合物 |
Country Status (38)
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI625121B (zh) | 2009-07-13 | 2018-06-01 | 基利科學股份有限公司 | 調節細胞凋亡信號之激酶的抑制劑 |
| HUE034911T2 (hu) | 2009-07-27 | 2018-03-28 | Gilead Sciences Inc | Fúzionált heterociklusos vegyületek mint ioncsatorna modulátorok |
| EP2588197B1 (en) | 2010-07-02 | 2014-11-05 | Gilead Sciences, Inc. | Fused heterocyclic compounds as ion channel modulators |
| WO2012154760A1 (en) | 2011-05-10 | 2012-11-15 | Gilead Sciences, Inc. | Fused heterocyclic compounds as sodium channel modulators |
| NO3175985T3 (enExample) | 2011-07-01 | 2018-04-28 | ||
| UY34171A (es) | 2011-07-01 | 2013-01-31 | Gilead Sciences Inc | Compuestos heterocíclicos fusionados como moduladores del canal iónico |
| EP2739732B1 (en) | 2011-08-05 | 2020-04-22 | Illumina, Inc. | Functionalization and purification of molecules by reversible group exchange |
| UY34573A (es) | 2012-01-27 | 2013-06-28 | Gilead Sciences Inc | Inhibidor de la quinasa que regula la señal de la apoptosis |
| JP2015504923A (ja) * | 2012-01-27 | 2015-02-16 | ギリアード サイエンシーズ， インコーポレイテッド | 後期ナトリウムイオンチャネル遮断剤およびカリウムイオンチャネル遮断剤を使用する併用療法 |
| JP6426694B2 (ja) | 2013-03-15 | 2018-11-21 | グローバル ブラッド セラピューティクス インコーポレイテッド | ヘモグロビンの修飾のための化合物及びその使用 |
| US20140329755A1 (en) * | 2013-05-01 | 2014-11-06 | Gilead Sciences, Inc. | Combination therapy for the treatment of arrhythmias or heart failure |
| MX2016001301A (es) * | 2013-08-01 | 2016-04-07 | Gilead Sciences Inc | Metodo para tratar la miocardiopatia hipertrofica. |
| EP3027190A1 (en) * | 2013-08-01 | 2016-06-08 | Gilead Sciences, Inc. | Compound and methods for treating long qt syndrome |
| CN105611923B (zh) * | 2013-09-10 | 2019-08-23 | 卓莫赛尔公司 | 用于治疗疼痛和糖尿病的钠通道调节剂 |
| EA201992707A1 (ru) | 2013-11-18 | 2020-06-30 | Глобал Блад Терапьютикс, Инк. | Соединения и их применения для модуляции гемоглобина |
| WO2015095370A1 (en) * | 2013-12-19 | 2015-06-25 | Gilead Sciences, Inc. | Fused heterocyclic compounds as ion channel modulators |
| CN104844535A (zh) | 2014-02-13 | 2015-08-19 | 吉利德科学公司 | 用于制备稠合杂环离子通道调节剂的方法 |
| CA2881544A1 (en) * | 2014-02-13 | 2015-08-13 | Anna Chiu | Solid forms of a late sodium current inhibitor |
| US20150283149A1 (en) * | 2014-04-02 | 2015-10-08 | Gilead Sciences, Inc. | Methods of treating patients having implantable cardiac devices |
| US10238636B2 (en) | 2014-09-24 | 2019-03-26 | Gilead Sciences, Inc. | Methods of treating liver disease |
| MA41252A (fr) | 2014-12-23 | 2017-10-31 | Gilead Sciences Inc | Formes solides d'un inhibiteur d'ask 1 |
| US9586933B2 (en) | 2014-12-23 | 2017-03-07 | Gilead Sciences, Inc. | Processes for preparing ASK1 inhibitors |
| RU2716136C2 (ru) | 2015-07-02 | 2020-03-06 | Ф. Хоффманн-Ля Рош Аг | Бициклические лактамы и способы их применения |
| WO2017007805A1 (en) | 2015-07-09 | 2017-01-12 | Gilead Sciences, Inc. | Intravenous formulations of a late sodium current inhibitor |
| US9815850B2 (en) | 2016-02-05 | 2017-11-14 | Denali Therapeutics Inc. | Compounds, compositions and methods |
| WO2017205536A2 (en) * | 2016-05-24 | 2017-11-30 | Genentech, Inc. | Therapeutic compounds and uses thereof |
| US11091483B2 (en) | 2016-08-12 | 2021-08-17 | Madera Therapeutics, LLC | Protein kinase regulators |
| WO2018048977A1 (en) | 2016-09-08 | 2018-03-15 | Auspex Pharmaceuticals, Inc. | Deuterium-substituted oxazepin compounds |
| JP7349359B2 (ja) | 2016-10-17 | 2023-09-22 | エフ． ホフマン－ラ ロシュ アーゲー | 二環式ピリドンラクタム及びその使用方法。 |
| AR110252A1 (es) | 2016-11-30 | 2019-03-13 | Gilead Sciences Inc | Compuestos heterocíclicos fusionados como inhibidores de la quinasa cam |
| LT3552017T (lt) | 2016-12-09 | 2022-05-10 | Denali Therapeutics Inc. | Junginiai, naudotini kaip ripk1 inhibitoriai |
| WO2018213491A1 (en) * | 2017-05-16 | 2018-11-22 | Praxis Precision Medicines, Inc. | Methods of treating epilepsy and neurodevelopmental disorders |
| SG10201913927VA (en) | 2017-05-17 | 2020-03-30 | Denali Therapeutics Inc | Kinase inhibitors and uses thereof |
| WO2019055877A1 (en) | 2017-09-15 | 2019-03-21 | Forma Therapeutics, Inc. | TETRAHYDROIMIDAZO QUINOLINE COMPOSITIONS AS INHIBITORS OF CBP / P300 |
| US11760701B2 (en) | 2018-02-27 | 2023-09-19 | The Research Foundation For The State University Of New Yrok | Difluoromethoxylation and trifluoromethoxylation compositions and methods for synthesizing same |
| US11649218B2 (en) | 2018-03-09 | 2023-05-16 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | C-Abl tyrosine kinase inhibitory compound embodiments and methods of making and using the same |
| IL279734B2 (en) | 2018-06-29 | 2024-11-01 | Forma Therapeutics Inc | Inhibiting creb binding protein (cbp) |
| EP3870173A4 (en) | 2018-10-24 | 2022-06-22 | Vanderbilt University | WDR5 INHIBITORS AND MODULATORS |
| KR102172595B1 (ko) * | 2018-12-19 | 2020-11-02 | 인하대학교 산학협력단 | 벤조옥사제핀 유도체 화합물을 포함하는 비만 예방 또는 치료용 약학 조성물 |
| TW202102494A (zh) | 2019-03-15 | 2021-01-16 | 美商弗瑪治療公司 | 抑制環amp-反應元件-結合蛋白(creb) |
| CN109879830A (zh) * | 2019-03-27 | 2019-06-14 | 安徽师范大学 | 一种含环外双键的氧氮杂环庚烷衍生物及其制备方法 |
| US12577227B2 (en) | 2019-06-04 | 2026-03-17 | Vanderbilt University | WDR5 inhibitors and modulators |
| US12692249B2 (en) | 2019-11-08 | 2026-07-28 | Vanderbilt University | WDR5 inhibitors and modulators |
| US11801243B2 (en) | 2020-09-23 | 2023-10-31 | Forma Therapeutics, Inc. | Bromodomain inhibitors for androgen receptor-driven cancers |
| US11795168B2 (en) | 2020-09-23 | 2023-10-24 | Forma Therapeutics, Inc. | Inhibiting cyclic amp-responsive element-binding protein (CREB) binding protein (CBP) |
| US12668594B2 (en) | 2020-12-23 | 2026-06-30 | Sudo Biosciences Limited | TYK2 inhibitors and uses thereof |
| KR20230159421A (ko) | 2021-02-19 | 2023-11-21 | 수도 바이오사이언시즈 리미티드 | Tyk2 억제제 및 이의 용도 |
| IL305119A (en) | 2021-02-19 | 2023-10-01 | Sudo Biosciences Ltd | Tyk2 inhibitors and uses thereof |
| TW202302583A (zh) | 2021-02-19 | 2023-01-16 | 英商蘇多生物科學有限公司 | Ｔｙｋ２抑制劑及其用途 |
| EP4463229A1 (en) | 2022-01-12 | 2024-11-20 | Denali Therapeutics Inc. | Crystalline forms of (s)-5-benzyl-n-(5-methyl-4-oxo-2, 3,4,5- tetrahydropyrido [3,2-b] [l,4]oxazepin-3-yl)-4h-l,2,4-triazole-3-carboxamide |
| WO2023143389A1 (zh) * | 2022-01-29 | 2023-08-03 | 江苏恒瑞医药股份有限公司 | 稠杂环类化合物、其制备方法及其在医药上的应用 |
| EP4495119A4 (en) | 2022-03-16 | 2025-06-25 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | FUSED HETEROCYCLIC COMPOUND, PREPARATION METHOD AND MEDICAL USE THEREOF |
| US20260116891A1 (en) * | 2022-04-22 | 2026-04-30 | Teijin Pharma Limited | Oxazepin Derivative |
Family Cites Families (225)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2867618A (en) | 1957-02-14 | 1959-01-06 | Dow Chemical Co | 3, 4-dihydro-2h-1, 3-benzoxazine |
| US2826575A (en) | 1957-05-06 | 1958-03-11 | Dow Chemical Co | 3, 3'-alkylenebis |
| NL128591C (enExample) | 1965-07-02 | |||
| US3441649A (en) | 1966-08-18 | 1969-04-29 | Univ Minnesota | Suppression of cardiac ventricular fibrillation and cardiac arrhythmias with bretylium tosylate |
| US3594372A (en) | 1968-08-13 | 1971-07-20 | American Home Prod | Pyrimido(4,5-e)(1,4)oxazepin-5-ones and derivatives thereof |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US4062881A (en) | 1974-07-26 | 1977-12-13 | Cincinnati Milacron Chemicals, Inc. | Sulfide containing tin stabilizers |
| US4230705A (en) | 1976-09-22 | 1980-10-28 | American Cyanamid Company | 6-Phenyl-1,2,4-triazolo[4,3-b]pyridazines and their uses in treating anxiety |
| US4242515A (en) | 1979-03-28 | 1980-12-30 | American Cyanamid Company | Substituted 3-alkyl-6-phenyl-1,2,4-triazolo-[4,3-a]pyridines |
| US4244953A (en) | 1979-10-24 | 1981-01-13 | American Cyanamid Company | Substituted 6-phenyl-5,6,7,8-tetrahydro-1,2,4-triazolo-[4,3-a]pyridines |
| JPS5675428A (en) | 1979-11-21 | 1981-06-22 | Ayanori Takabe | Hypoglycemic agent containing procainamide hydrochloride |
| US4326525A (en) | 1980-10-14 | 1982-04-27 | Alza Corporation | Osmotic device that improves delivery properties of agent in situ |
| US4812565A (en) * | 1982-09-30 | 1989-03-14 | A. H. Robins Company, Incorporated | Fused aromatic oxazepinones, thiazepinones, diazepinones and sulfur analogs thereof |
| DE3382028D1 (de) * | 1982-09-30 | 1991-01-10 | Robins Co Inc A H | Kondensierte aromatische oxazepinone und sulphuranaloge, ihrer herstellung und verwendung als histamin-antagonist. |
| US5364620A (en) | 1983-12-22 | 1994-11-15 | Elan Corporation, Plc | Controlled absorption diltiazem formulation for once daily administration |
| US4654343A (en) | 1985-10-31 | 1987-03-31 | American Cyanamid Company | N-substituted-N[3-(1,2,4-triazolo[4,3-b]pyridazin-6-yl)phenyl]alkanamides, carbamates and ureas |
| US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| JPH061779B2 (ja) | 1987-07-31 | 1994-01-05 | 田中電子工業株式会社 | 半導体装置の製造方法 |
| RO96410B1 (ro) * | 1987-02-16 | 1989-03-02 | Institutul Politehnic | Derivati de 1,4-benzoxazepinona si procedeu pentru prepararea lor |
| US4746655A (en) | 1987-06-10 | 1988-05-24 | A. H. Robins Company, Incorporated | Fused aromatic-spiropiperidine oxazepinones(and thiones) |
| US4992445A (en) | 1987-06-12 | 1991-02-12 | American Cyanamid Co. | Transdermal delivery of pharmaceuticals |
| US5001139A (en) | 1987-06-12 | 1991-03-19 | American Cyanamid Company | Enchancers for the transdermal flux of nivadipine |
| US4902514A (en) | 1988-07-21 | 1990-02-20 | Alza Corporation | Dosage form for administering nilvadipine for treating cardiovascular symptoms |
| DE4010488A1 (de) | 1990-03-31 | 1991-10-02 | Hoechst Ag | Benzoxazinderivate, verfahren zu ihrer herstellung und ihre verwendung zum behandeln oder zur prophylaxe von krankheiten |
| CA2044564A1 (en) | 1990-06-28 | 1991-12-29 | Quirico Branca | Amino acid derivatives |
| CN1060467A (zh) | 1990-09-25 | 1992-04-22 | 武田药品工业株式会社 | 1，3-苯并嗪衍生物、其生产方法和用途 |
| JPH04209692A (ja) | 1990-12-03 | 1992-07-31 | Asahi Glass Co Ltd | フォトクロミック材料 |
| EP0522606B1 (en) | 1991-05-10 | 1996-04-03 | Takeda Chemical Industries, Ltd. | Pyridine derivatives, their production and use |
| ATE228115T1 (de) * | 1991-06-28 | 2002-12-15 | Smithkline Beecham Corp | Bizyklische fibrinogenantagonisten |
| US5939412A (en) * | 1992-06-26 | 1999-08-17 | Smithkline Beecham Corporation | Bicyclic fibrinogen antagonists |
| US5565449A (en) * | 1991-10-18 | 1996-10-15 | Genentech, Inc. | Nonpeptidyl integrin inhibitors having specificity for the GPIIb IIIa receptor |
| US5250679A (en) * | 1991-10-18 | 1993-10-05 | Genentech, Inc. | Nonpeptidyl platelet aggregation inhibitors having specificity for the GPIIb III.sub. receptor |
| US5272158A (en) | 1991-10-29 | 1993-12-21 | Merck & Co., Inc. | Fibrinogen receptor antagonists |
| JPH061779A (ja) | 1992-02-06 | 1994-01-11 | Wakamoto Pharmaceut Co Ltd | ベンズオキサジノン誘導体 |
| JPH06107647A (ja) | 1992-08-12 | 1994-04-19 | Takeda Chem Ind Ltd | １，３−ベンゾオキサジン誘導体の製造法 |
| US6011150A (en) | 1992-11-13 | 2000-01-04 | Tanabe Seiyaku Co., Ltd. | Azetidinone compound and process for preparation thereof |
| US5442055A (en) | 1992-11-13 | 1995-08-15 | Tanabe Seiyaku Co., Ltd. | Azetidinone compound and process for preparation thereof |
| GB9225860D0 (en) | 1992-12-11 | 1993-02-03 | Smithkline Beecham Plc | Novel treatment |
| GB9226302D0 (en) | 1992-12-17 | 1993-02-10 | Smithkline Beecham Plc | Pharmaceuticals |
| US5550229A (en) | 1993-06-23 | 1996-08-27 | Tanabe Seiyaku Co., Ltd. | Alkylation process for preparing azetidinone compound and starting compound therefor |
| DE19526173A1 (de) | 1995-07-18 | 1997-01-30 | Hoechst Ag | Polyfullerenaddukte, Verfahren zu ihrer regioselektiven Herstellung und deren Verwendung |
| JPH09157262A (ja) | 1995-12-08 | 1997-06-17 | Tanabe Seiyaku Co Ltd | アゼチジノン誘導体及びその合成中間体の製法 |
| US5773186A (en) | 1996-02-19 | 1998-06-30 | Fuji Photo Film Co., Ltd. | Heat-sensitive recording material |
| GB9619492D0 (en) | 1996-09-18 | 1996-10-30 | Smithkline Beecham Plc | Novel treatment |
| US6159979A (en) | 1997-04-18 | 2000-12-12 | Smithkline Beecham P.L.C. | Bicyclic aryl or a bicyclic heterocyclic ring containing compounds having a combined 5HT1A, 5HT1B and 5HT1D receptor antagonistic activity |
| EP0999208A4 (en) | 1997-05-30 | 2001-08-08 | Meiji Seika Kaisha | NITROGEN-BASED HETEROCYCLIC COMPOUNDS AND MEDICINES FOR TREATING HYPERLIPEMIA THAT CONTAIN THEM |
| JP3964053B2 (ja) | 1997-07-10 | 2007-08-22 | 三井化学株式会社 | 遷移金属化合物からなるオレフィン重合用触媒ならびに重合方法 |
| ES2165193T3 (es) | 1997-09-08 | 2002-03-01 | Unilever Nv | Metodo para aumentar la actividad de una enzima. |
| MXPA00007135A (es) | 1998-01-21 | 2002-11-07 | Merck Sharp & Dohme | Derivados de triazolo-piridazina como ligandos para receptores gaba. |
| AU2594799A (en) * | 1998-02-11 | 1999-08-30 | Du Pont Pharmaceuticals Company | Novel cyclic sulfonamide derivatives as metalloproteinase inhibitors |
| RU2214405C2 (ru) | 1998-02-18 | 2003-10-20 | НьюроСёрч А/С | Новые соединения и их применение в качестве положительных модуляторов амра-рецепторов |
| US6479506B1 (en) | 1998-06-16 | 2002-11-12 | Merck Sharp & Dohme Ltd. | Triazolo-pyridine derivatives as ligands for GABA receptors |
| EP1123297A1 (en) | 1998-10-21 | 2001-08-16 | Novo Nordisk A/S | New compounds, their preparation and use |
| BR0009650A (pt) | 1999-04-09 | 2002-01-02 | Meiji Seika Kaisha | Composto, composição farmacêutica, processos para inibir a secreção de uma lipoproteìna contendo apolipoproteìna b, para inibir a biossìntese de triglicerìdeos e para prevenir ou tratar hiperlipidemia, doenças arterioscleróticas e pancreatite, e, uso do composto |
| CA2373073A1 (en) | 1999-05-07 | 2000-11-16 | Takeda Chemical Industries, Ltd. | Cyclic compounds and uses thereof |
| US6121916A (en) | 1999-07-16 | 2000-09-19 | Eaton-Vorad Technologies, L.L.C. | Method and apparatus for recognizing stationary objects with a moving side-looking radar |
| MXPA02002126A (es) | 1999-08-27 | 2002-09-18 | Procter & Gamble | Metodos de lavanderia que conservan el color, que emplean componentes de formulacion zwitterionicos. |
| EP1206517A1 (en) | 1999-08-27 | 2002-05-22 | The Procter & Gamble Company | Color safe laundry methods employing cationic formulation components |
| MXPA02002129A (es) | 1999-08-27 | 2002-09-18 | Procter & Gamble | Componentes de formulacion de accion rapida, composiciones y metodos para lavanderia que los emplean. |
| JP2003508581A (ja) | 1999-08-27 | 2003-03-04 | ザ、プロクター、エンド、ギャンブル、カンパニー | 処方成分の制御された有効化法、それを使用する組成物および洗濯方法 |
| CN1165525C (zh) | 1999-08-27 | 2004-09-08 | 宝洁公司 | 漂白增效剂组分、组合物及洗涤方法 |
| WO2001016274A1 (en) | 1999-08-27 | 2001-03-08 | The Procter & Gamble Company | Stable formulation components, compositions and laundry methods employing same |
| JP2003508587A (ja) | 1999-08-27 | 2003-03-04 | ザ、プロクター、エンド、ギャンブル、カンパニー | 安定性増強配合成分、これを用いた組成物および洗濯方法 |
| IL135092A0 (en) | 2000-03-15 | 2001-05-20 | Kidron Agrochem Ltd | A composition for the control of pests |
| EP1286994A1 (en) | 2000-05-15 | 2003-03-05 | Darwin Discovery Limited | Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity |
| WO2002010135A1 (en) | 2000-08-01 | 2002-02-07 | Ono Pharmaceutical Co., Ltd. | 3,4-dihydroisoquinoline derivative compounds and drugs containing these compounds as the active ingredient |
| JP2004521079A (ja) | 2000-08-29 | 2004-07-15 | ファルマシア・コーポレーション | アルファーｖベータ３アンタゴニストとして有用な二環式環系を含有する化合物 |
| JP2002205992A (ja) | 2000-11-08 | 2002-07-23 | Takeda Chem Ind Ltd | 二環式トリアゾロン誘導体およびそれを含有する除草剤 |
| EP1695716A2 (en) | 2000-12-26 | 2006-08-30 | Sankyo Company, Limited | Medicinal compositions containing diuretics and insulin sensitizers |
| OA12552A (en) | 2001-03-09 | 2006-06-06 | Pfizer Prod Inc | Triazolopyridines as anti-inflammatory agents. |
| US6998408B2 (en) | 2001-03-23 | 2006-02-14 | Bristol-Myers Squibb Pharma Company | 6-5, 6-6, or 6-7 Heterobicycles as factor Xa inhibitors |
| US20030114448A1 (en) | 2001-05-31 | 2003-06-19 | Millennium Pharmaceuticals, Inc. | Inhibitors of factor Xa |
| JP2005089298A (ja) | 2001-09-18 | 2005-04-07 | Japan Tobacco Inc | ナフタレン化合物及びその医薬用途 |
| GB0124627D0 (en) | 2001-10-15 | 2001-12-05 | Smithkline Beecham Plc | Novel compounds |
| EP1451153B1 (en) | 2001-11-13 | 2007-09-26 | Schering Corporation | Nk1 antagonists |
| US7196108B2 (en) | 2002-03-08 | 2007-03-27 | Incyte San Diego Inc. | Bicyclic heterocycles for the treatment of diabetes and other diseases |
| JP2003277384A (ja) | 2002-03-26 | 2003-10-02 | Kyorin Pharmaceut Co Ltd | 縮合ニ環式ピリジン誘導体 |
| JP2003321461A (ja) | 2002-04-25 | 2003-11-11 | Kyorin Pharmaceut Co Ltd | 縮合ビフェニル誘導体 |
| US20040152696A1 (en) * | 2002-08-01 | 2004-08-05 | Euro-Celtique S.A. | 2-substituted bicyclic benzoheterocyclic compounds and their use as sodium channel blockers |
| CA2497658A1 (en) | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | Chromone derivatives as matrix metalloproteinase inhibitors |
| MXPA05001786A (es) | 2002-08-13 | 2005-04-25 | Warner Lambert Co | Derivados de azaisoquinolina como inhibidores de la metaloproteinasa de matriz. |
| US20040242572A1 (en) | 2002-08-24 | 2004-12-02 | Boehringer Ingelheim International Gmbh | New carboxamide compounds having melanin concentrating hormone antagonistic activity, pharmaceutical preparations comprising these compounds and process for their manufacture |
| DE10238865A1 (de) | 2002-08-24 | 2004-03-11 | Boehringer Ingelheim International Gmbh | Neue Carbonsäureamid-Verbindungen mit MCH-antagonistischer Wirkung, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
| US7005523B2 (en) | 2002-08-30 | 2006-02-28 | Pfizer Inc. | Cycloalkyl-[4-(trifluorophenyl)-oxazol-5yl]-triazolo-pyridines |
| PA8579601A1 (es) | 2002-08-30 | 2004-05-07 | Pfizer Prod Inc | Compuestos antiinflamatorios de di y trifloruro-triazolo-piridinas |
| WO2004026292A1 (ja) | 2002-09-20 | 2004-04-01 | Tsumura & Co. | 鎮咳薬 |
| US20040204404A1 (en) | 2002-09-30 | 2004-10-14 | Robert Zelle | Human N-type calcium channel blockers |
| GB0223730D0 (en) | 2002-10-11 | 2002-11-20 | Novartis Ag | Organic compounds |
| AU2003294235A1 (en) | 2002-10-22 | 2004-05-13 | The Trustees Of The University Of Pennsylvania | Fragments and activity of rel protein in m. tuberculosis adn other uses thereof |
| JP4413863B2 (ja) | 2002-11-07 | 2010-02-10 | メルク エンド カムパニー インコーポレーテッド | 糖尿病の治療又は予防のためのジペチジルペプチダーゼ阻害剤としてのフェニルアラニン誘導体 |
| CN100430386C (zh) | 2002-11-07 | 2008-11-05 | 默克公司 | 苯丙氨酸衍生物作为二肽基肽酶抑制剂用于治疗或预防糖尿病 |
| PL378366A1 (pl) | 2003-01-13 | 2006-04-03 | Cortex Pharmaceuticals, Inc. | Sposób leczenia osłabienia funkcji poznawczych spowodowanego deprywacją snu i stresem |
| MY142651A (en) | 2003-03-18 | 2010-12-15 | Merck Sharp & Dohme | Biaryl substituted triazoles as sodium channel blockers |
| DE10317526A1 (de) | 2003-04-16 | 2004-11-04 | Degussa Ag | Verfahren zum Delignifizieren von ligninhaltigen Faserstoffen |
| CA2521625A1 (en) | 2003-04-17 | 2004-11-04 | Merck & Co., Inc. | Heterocyclic cyclopentyl tetrahydroisoquinoline and tetrahydropyridopyridine modulators of chemokine receptor activity |
| MXPA05010174A (es) | 2003-04-25 | 2005-11-08 | Lundbeck & Co As H | Derivados de indol e indolina sustituidos. |
| WO2004101509A2 (en) | 2003-05-06 | 2004-11-25 | Case Western Reserve University | Functionalized benzoxazines, polymers and copolymers thereof |
| EP1646614A4 (en) | 2003-07-01 | 2008-09-10 | Merck & Co Inc | OPHTHALMIC COMPOSITIONS FOR THE TREATMENT OF OCCULAR HYPERTONIA |
| CN1822833A (zh) | 2003-07-21 | 2006-08-23 | 索尔瓦药物有限公司 | 3,7－二氮杂双环[3,3,1]壬烷化合物在治疗和/或预防男性患者心律失常中的用途 |
| EP1663994B1 (en) | 2003-08-05 | 2012-03-07 | Vertex Pharmaceuticals Incorporated | Tetrahydroquinazoline compounds as inhibitors of voltage-gated ion channels |
| US20050239767A1 (en) | 2003-10-28 | 2005-10-27 | Chan Michael K | Intermolecular SNAr of the heterocycle-activated nitro and fluoro groups-application in the synthesis of polyazamacrocyclic ligands |
| AU2004305318A1 (en) | 2003-12-18 | 2005-07-07 | Pfizer Products Inc. | Methods of treating acute inflammation in animals with p38 MAP kinase inhibitors |
| BRPI0508140B1 (pt) | 2004-03-05 | 2015-03-17 | Nissan Chemical Ind Ltd | Composto benzamida substituída por isoxazolina da fórmula (1); da fórmula (2) substituído por 3,5-bis (aril substituído); da fórmula (4) substituída por alquinibenzeno ou um sal do mesmo; "pesticida, agroquímico, inseticida, parasiticida contendo como ingrediente ativo um ou mais composto benzamida substituída por isoxazolina e sal do mesmo" |
| US7306631B2 (en) | 2004-03-30 | 2007-12-11 | The Procter & Gamble Company | Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof |
| GB0412986D0 (en) | 2004-06-10 | 2004-07-14 | Xention Discovery Ltd | Compounds |
| WO2006002470A1 (en) | 2004-06-30 | 2006-01-12 | Monash University | Chiral ligands for asymmetric catalysis |
| JP2006063064A (ja) | 2004-07-27 | 2006-03-09 | Takeda Chem Ind Ltd | 受容体作動剤 |
| JP2007297283A (ja) | 2004-07-28 | 2007-11-15 | Santen Pharmaceut Co Ltd | 新規桂皮酸関連化合物 |
| EP1784390A2 (en) * | 2004-08-13 | 2007-05-16 | Amgen Inc. | Substituted benzofused heterocycles |
| US7521457B2 (en) | 2004-08-20 | 2009-04-21 | Boehringer Ingelheim International Gmbh | Pyrimidines as PLK inhibitors |
| DE602005022320D1 (de) | 2004-08-23 | 2010-08-26 | Merck Sharp & Dohme | Kondensierte triazolderivate als dipeptidylpeptidase-iv-hemmer zur behandlung bzw. prävention von diabetes |
| AU2005285083B2 (en) | 2004-09-13 | 2011-03-10 | Merck Sharp & Dohme Corp. | Tricyclic anilide spirohydantoin CGRP receptor antagonists |
| TW200624431A (en) | 2004-09-24 | 2006-07-16 | Hoffmann La Roche | Phthalazinone derivatives, their manufacture and use as pharmaceutical agents |
| WO2006048727A1 (en) | 2004-11-02 | 2006-05-11 | Pfizer Products Inc. | Piperazinylphenalkyl lactam/amine ligands for the 5ht1b receptor |
| JP2006203875A (ja) | 2004-12-24 | 2006-08-03 | Matsushita Electric Ind Co Ltd | 受信装置 |
| WO2006091897A2 (en) | 2005-02-25 | 2006-08-31 | Adenosine Therapeutics, Llc | Derivatives of 8-substituted xanthines |
| TW200643015A (en) | 2005-03-11 | 2006-12-16 | Akzo Nobel Nv | 2-(4-oxo-4H-quinazolin-3-yl)acetamide derivatives |
| WO2006113432A2 (en) * | 2005-04-14 | 2006-10-26 | Smithkline Beecham Corporation | Compounds, compositions and methods |
| AR056317A1 (es) | 2005-04-20 | 2007-10-03 | Xenon Pharmaceuticals Inc | Compuestos de oxindol y composicion farmaceutica |
| SI1881823T1 (sl) | 2005-05-17 | 2015-04-30 | Sarcode Bioscience Inc. | Sestavki in postopki za zdravljenje bolezni oäśesa |
| TW200714597A (en) | 2005-05-27 | 2007-04-16 | Astrazeneca Ab | Chemical compounds |
| US7572807B2 (en) | 2005-06-09 | 2009-08-11 | Bristol-Myers Squibb Company | Heteroaryl 11-beta-hydroxysteroid dehydrogenase type I inhibitors |
| US7632837B2 (en) | 2005-06-17 | 2009-12-15 | Bristol-Myers Squibb Company | Bicyclic heterocycles as cannabinoid-1 receptor modulators |
| MX2007015772A (es) | 2005-06-17 | 2008-02-22 | Wyeth Corp | Compuestos utiles como inhibidores de serotonina y agonistas y antagonistas de 5-ht-1a. |
| TW200726765A (en) | 2005-06-17 | 2007-07-16 | Bristol Myers Squibb Co | Triazolopyridine cannabinoid receptor 1 antagonists |
| WO2007004028A2 (en) | 2005-06-30 | 2007-01-11 | Ranbaxy Laboratories Limited | Processes for the preparation of penems and its intermediate |
| EP1932549B1 (en) | 2005-08-26 | 2016-12-28 | AMNOS Co., Ltd. | Dried amnion and method for drying treatment of amnion |
| CA2621255A1 (en) | 2005-09-21 | 2007-04-05 | Incyte Corporation | Amido compounds and their use as pharmaceuticals |
| US7482360B2 (en) | 2005-09-23 | 2009-01-27 | Schering Corporation | Fused tetracyclic mGluR1 antagonists as therapeutic agents |
| US20090022694A1 (en) | 2005-10-18 | 2009-01-22 | Distefano Peter | Sirt1 inhibition |
| TW200804290A (en) | 2005-11-15 | 2008-01-16 | Astrazeneca Ab | Compounds and uses thereof |
| EP1954135B1 (en) | 2005-11-18 | 2012-10-10 | Merck Sharp & Dohme Corp. | Spirolactam aryl cgrp receptor antagonists |
| EP1954268B1 (en) | 2005-11-18 | 2012-09-26 | Merck Sharp & Dohme Corp. | Spirolactam bicyclic cgrp receptor antagonists |
| TW200734342A (en) | 2005-12-15 | 2007-09-16 | Astrazeneca Ab | New compounds for the treatment of cardiac arrhythmias |
| CN101330914A (zh) | 2005-12-16 | 2008-12-24 | 爱尔康公司 | 使用alk5调节剂控制眼内压 |
| US8013073B2 (en) | 2005-12-30 | 2011-09-06 | Chevron Oronite Company Llc | Method for preparing polyolefins containing vinylidine end groups using nonaromatic heterocyclic compounds |
| JP2009531390A (ja) | 2006-03-31 | 2009-09-03 | ノバルティス アクチエンゲゼルシャフト | 有機化合物 |
| JP5528699B2 (ja) * | 2006-05-16 | 2014-06-25 | 武田薬品工業株式会社 | 縮合複素環化合物およびその用途 |
| EP2043654A2 (en) | 2006-06-12 | 2009-04-08 | Vertex Pharmaceuticals, Inc. | Thienopyrimidines useful as modulators of ion channels |
| US20080011523A1 (en) | 2006-06-29 | 2008-01-17 | Packard Thomas G | Rotor energy augmented vehicle |
| EP2035372A1 (en) | 2006-06-29 | 2009-03-18 | Arena Pharmaceuticals, Inc. | Modulators of the histamine h3-receptor useful for the treatment of disorders related thereto |
| ES2431466T3 (es) | 2006-06-30 | 2013-11-26 | Sunesis Pharmaceuticals, Inc. | Inhibidores de piridinonil pdk1 |
| WO2008007661A1 (en) * | 2006-07-11 | 2008-01-17 | Takeda Pharmaceutical Company Limited | Tricyclic heterocyclic compound and use thereof |
| AU2007272009A1 (en) | 2006-07-12 | 2008-01-17 | Syngenta Limited | Triazolopyridine derivatives as herbicides |
| PE20121506A1 (es) | 2006-07-14 | 2012-11-26 | Amgen Inc | Compuestos triazolopiridinas como inhibidores de c-met |
| US8217177B2 (en) | 2006-07-14 | 2012-07-10 | Amgen Inc. | Fused heterocyclic derivatives and methods of use |
| JO2868B1 (en) | 2006-08-22 | 2015-03-15 | رانبكسي لابوراتوريز ليمتد | Inhibitors of metabolic protein protein enzyme |
| CN101553224A (zh) | 2006-10-06 | 2009-10-07 | 艾博特公司 | 新型咪唑并噻唑和咪唑并唑 |
| WO2008118141A2 (en) | 2006-10-17 | 2008-10-02 | Acadia Pharmaceuticals Inc. | Use of cannabinoid modulating compounds in combination with other therapeutic compounds for adjunctive therapy |
| MX2009004426A (es) | 2006-10-23 | 2009-08-12 | Cephalon Inc | Derivados biciclicos fusionados de 2,4-diaminopirimidina como inhibidores alk y c-met. |
| CA2667826C (en) | 2006-10-28 | 2013-10-08 | Methylgene Inc. | Inhibitors of histone deacetylase |
| EP2128134A1 (en) | 2006-11-02 | 2009-12-02 | Shionogi&Co., Ltd. | Sulfonylurea derivative capable of selectively inhibiting mmp-13 |
| US20080153840A1 (en) | 2006-12-21 | 2008-06-26 | Luiz Belardinelli | Reduction of cardiovascular symptoms |
| US8076350B2 (en) | 2006-12-22 | 2011-12-13 | Abbott Laboratories | Spirocyclic azaadamantane derivatives and methods of use |
| WO2008094909A2 (en) | 2007-01-29 | 2008-08-07 | Xenon Pharmaceuticals Inc. | Quinazolinone and fused pyrimidinone compounds and their use in treating sodium channel-mediated diseases or conditions |
| US20100144715A1 (en) | 2007-02-28 | 2010-06-10 | Hoyt Scott B | Substituted Benzodiazepinones, Benzoxazepinones and Benzothiazepinones as Sodium Channel Blockers |
| EP2123644B1 (en) | 2007-03-07 | 2014-12-17 | Takeda Pharmaceutical Company Limited | Benzoxazepine derivatives and use thereof |
| GB0706072D0 (en) | 2007-03-28 | 2007-05-09 | Sterix Ltd | Compound |
| JP2010523713A (ja) | 2007-04-12 | 2010-07-15 | ギリアード・パロ・アルト・インコーポレイテッド | インスリン分泌を増強するためのラノラジン |
| CN101657198A (zh) * | 2007-04-12 | 2010-02-24 | Cv医药有限公司 | 增强胰岛素分泌的雷诺嗪 |
| WO2008134553A1 (en) | 2007-04-26 | 2008-11-06 | Xenon Pharmaceuticals Inc. | Methods of using bicyclic compounds in treating sodium channel-mediated diseases |
| WO2008144483A2 (en) * | 2007-05-18 | 2008-11-27 | Armgo Pharma, Inc. | Agents for treating disorders involving modulation of ryanodine receptors |
| WO2009005675A1 (en) | 2007-06-28 | 2009-01-08 | Abbott Laboratories | Novel triazolopyridazines |
| US20090012103A1 (en) * | 2007-07-05 | 2009-01-08 | Matthew Abelman | Substituted heterocyclic compounds |
| US20090036425A1 (en) | 2007-08-02 | 2009-02-05 | Pfizer Inc | Substituted bicyclolactam compounds |
| US20110263569A1 (en) | 2007-08-22 | 2011-10-27 | President And Fellows Of Harvard College | Ryanodine channel binders and uses thereof |
| US20090069300A1 (en) | 2007-09-12 | 2009-03-12 | Wyeth | Isoquinolinyl and isoindolinyl derivatives as histamine-3 antagonists |
| US8119658B2 (en) | 2007-10-01 | 2012-02-21 | Bristol-Myers Squibb Company | Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors |
| EP2231662B1 (en) | 2007-12-19 | 2011-06-22 | Genentech, Inc. | 8-anilinoimidazopyridines and their use as anti-cancer and/or anti-inflammatory agents |
| PE20091339A1 (es) | 2007-12-21 | 2009-09-26 | Glaxo Group Ltd | Derivados de oxadiazol con actividad sobre receptores s1p1 |
| US20110112079A1 (en) | 2008-01-09 | 2011-05-12 | Thomas Craig J | Phosphodiesterase inhibitors |
| BRPI0908428A2 (pt) | 2008-02-06 | 2015-12-08 | Gilead Sciences Inc | uso de ranozalina para tratar a dor. |
| JPWO2009101917A1 (ja) | 2008-02-13 | 2011-06-09 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ビシクロアミン誘導体 |
| JP2009286773A (ja) | 2008-03-14 | 2009-12-10 | Bayer Cropscience Ag | 殺虫性縮環式アリール類 |
| WO2009137499A1 (en) | 2008-05-05 | 2009-11-12 | Envivo Pharmaceuticals, Inc. | Inhibitors of histone deacetylase |
| US20110288070A1 (en) | 2008-05-05 | 2011-11-24 | ROGERS Kathryn | Methods for treating cognitive disorders using inhibitors of histone deacetylase |
| DE102008024182A1 (de) | 2008-05-19 | 2009-11-26 | Merck Patent Gmbh | Verbindungen für organische elektronische Vorrichtung |
| MX2010013399A (es) | 2008-06-06 | 2010-12-21 | Abbott Lab | Nuevos compuestos de 1,2,4-oxadiazol y sus metodos de uso. |
| CN102124000B (zh) | 2008-06-17 | 2014-09-17 | 阿斯利康(瑞典)有限公司 | 吡啶化合物 |
| US8338477B2 (en) | 2008-07-11 | 2012-12-25 | Neumedics | Tetracycline derivatives with reduced antibiotic activity and neuroprotective benefits |
| WO2010018686A1 (ja) | 2008-08-12 | 2010-02-18 | 日本曹達株式会社 | 含窒素ヘテロ環誘導体および農園芸用殺菌剤 |
| WO2010022001A1 (en) | 2008-08-18 | 2010-02-25 | Im&T Research, Inc. | Methods for preparing fluoroalkyl arylsulfinyl compounds and fluorinated compounds thereto |
| JP2012502047A (ja) | 2008-09-04 | 2012-01-26 | ギリアード サイエンシーズ， インコーポレイテッド | 心房細動を治療する方法 |
| WO2010053757A1 (en) * | 2008-10-29 | 2010-05-14 | Gilead Palo Alto, Inc. | 2 -oxoquinoxalin blockers of the late sodium channel |
| WO2010056527A2 (en) * | 2008-10-30 | 2010-05-20 | Gilead Palo Alto, Inc. | Fused heterocyclic compounds as ion channel modulators |
| WO2010074807A1 (en) * | 2008-10-30 | 2010-07-01 | Gilead Palo Alto, Inc. | 3, 4-dihydroquinolin-2 ( 1h ) -one derivatives as sodium channel modulators |
| US20100125091A1 (en) * | 2008-11-14 | 2010-05-20 | Gilead Palo Alto, Inc. | Substituted heterocyclic compounds as ion channel modulators |
| WO2010068461A1 (en) * | 2008-11-25 | 2010-06-17 | Gilead Palo Alto, Inc. | Co-administration of ranolazine and cardiac glycosides |
| CA2746221A1 (en) | 2008-12-08 | 2010-07-08 | Sirtris Pharmaceuticals, Inc. | Isoindolinone and related analogs as sirtuin modulators |
| RU2016116516A (ru) | 2008-12-08 | 2018-12-07 | Мандифарма Интернэшнл Корпорейшн Лимитед | Композиции ингибиторов тирозинкиназных рецепторов белков |
| JP5271069B2 (ja) | 2008-12-24 | 2013-08-21 | 三和シヤッター工業株式会社 | 開閉装置 |
| CA2747419C (en) * | 2009-01-12 | 2014-07-08 | Icagen, Inc. | Sulfonamide derivatives |
| FR2943342B1 (fr) * | 2009-03-20 | 2011-03-04 | Servier Lab | Nouveaux derives de benzothiadiazepines,leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
| EA201190224A1 (ru) | 2009-03-27 | 2012-03-30 | Пресидио Фармасьютикалс, Инк. | Ингибиторы гепатита c, содержащие конденсированные кольца |
| WO2010118208A1 (en) * | 2009-04-09 | 2010-10-14 | Exelixis, Inc. | Benzoxazepin-4- (5h) -yl derivatives and their use to treat cancer |
| HUE034911T2 (hu) | 2009-07-27 | 2018-03-28 | Gilead Sciences Inc | Fúzionált heterociklusos vegyületek mint ioncsatorna modulátorok |
| TWI423980B (zh) | 2009-09-28 | 2014-01-21 | Hoffmann La Roche | 苯并氧氮呯ｐｉ３ｋ抑制劑化合物及使用方法 |
| US20120264636A1 (en) | 2009-10-07 | 2012-10-18 | Decode Genetics Ehf. | Genetic variants indicative of vascular conditions |
| WO2011056985A2 (en) | 2009-11-04 | 2011-05-12 | Gilead Sciences, Inc. | Substituted heterocyclic compounds |
| CN102791687B (zh) | 2009-12-18 | 2015-02-11 | 北京凯因科技股份有限公司 | C型肝炎病毒复制的新型抑制剂 |
| TWI508726B (zh) | 2009-12-21 | 2015-11-21 | Gilead Sciences Inc | 治療心房纖維性顫動之方法 |
| EP2588197B1 (en) | 2010-07-02 | 2014-11-05 | Gilead Sciences, Inc. | Fused heterocyclic compounds as ion channel modulators |
| WO2012019071A1 (en) * | 2010-08-06 | 2012-02-09 | The Trustees Of Columbia University In The City Of New York | Methods of preventing and treating sarcopenia |
| WO2012019076A1 (en) * | 2010-08-06 | 2012-02-09 | The Trustees Of Columbia University In The City Of New York | Compositions and methods for preventing and treating cardiac ischemia/reperfusion injury |
| WO2012037105A1 (en) * | 2010-09-14 | 2012-03-22 | The Trustees Of Columbia University In The City Of New York | Methods of treating, ameliorating or preventing stress-induced neuronal disorders and diseases |
| WO2012036233A1 (ja) | 2010-09-17 | 2012-03-22 | 塩野義製薬株式会社 | メラニン凝集ホルモン受容体アンタゴニスト活性を有する縮合へテロ環誘導体 |
| ME02367B (me) | 2010-09-21 | 2016-06-20 | Purdue Pharma Lp | Analozi buprenorfina kao agonisti i/ili antagonisti opioidnog receptora |
| US8999967B2 (en) | 2010-09-29 | 2015-04-07 | Presidio Pharmaceuticals, Inc. | Tricyclic fused ring inhibitors of hepatitis C |
| EP2643316A2 (en) * | 2010-11-24 | 2013-10-02 | Exelixis, Inc. | Benzoxazepines as inhibitors of p13k/mtor and methods of their use and manufacture |
| JP5675428B2 (ja) | 2011-02-25 | 2015-02-25 | サンドビック株式会社 | ベルトプレス装置 |
| KR20140032383A (ko) | 2011-03-21 | 2014-03-14 | 에프. 호프만-라 로슈 아게 | Pi3k p110 델타에 대하여 선택적인 벤즈옥사제핀 화합물 및 이의 사용 방법 |
| WO2012154760A1 (en) | 2011-05-10 | 2012-11-15 | Gilead Sciences, Inc. | Fused heterocyclic compounds as sodium channel modulators |
| US8753674B2 (en) | 2011-06-03 | 2014-06-17 | Signpath Pharma Inc. | Liposomal mitigation of drug-induced long QT syndrome and potassium delayed-rectifier current |
| WO2013004551A1 (en) | 2011-07-01 | 2013-01-10 | Bayer Intellectual Property Gmbh | Hydroxymethylaryl-substituted pyrrolotriazines as alk1 inhibitors |
| TWI567061B (zh) | 2011-07-01 | 2017-01-21 | 吉李德科學股份有限公司 | 用於治療成癮之化合物 |
| NO3175985T3 (enExample) | 2011-07-01 | 2018-04-28 | ||
| UY34171A (es) | 2011-07-01 | 2013-01-31 | Gilead Sciences Inc | Compuestos heterocíclicos fusionados como moduladores del canal iónico |
| WO2013043925A1 (en) | 2011-09-21 | 2013-03-28 | Gilead Sciences, Inc. | Sodium channel blockers reduce glucagon secretion |
| WO2013097052A1 (en) | 2011-12-30 | 2013-07-04 | Abbott Laboratories | Bromodomain inhibitors |
| US8623860B2 (en) | 2011-12-30 | 2014-01-07 | Boehringer Ingelheim International Gmbh | Azetidine derivatives, pharmaceutical compositions and uses thereof |
| JP2015504923A (ja) | 2012-01-27 | 2015-02-16 | ギリアード サイエンシーズ， インコーポレイテッド | 後期ナトリウムイオンチャネル遮断剤およびカリウムイオンチャネル遮断剤を使用する併用療法 |
| WO2013185764A2 (en) | 2012-06-13 | 2013-12-19 | Acesion Pharma | Pharmaceutical compositions for combination therapy |
| WO2014134419A1 (en) | 2013-03-01 | 2014-09-04 | Gilead Sciences, Inc. | Use of ikach blockers for the treatment of cardiac diseases |
| CA2881544A1 (en) | 2014-02-13 | 2015-08-13 | Anna Chiu | Solid forms of a late sodium current inhibitor |
| CN104844535A (zh) | 2014-02-13 | 2015-08-19 | 吉利德科学公司 | 用于制备稠合杂环离子通道调节剂的方法 |
-
2012
- 2012-06-28 UY UY0001034171A patent/UY34171A/es not_active Application Discontinuation
- 2012-06-28 TW TW104100530A patent/TWI549944B/zh not_active IP Right Cessation
- 2012-06-28 TW TW101123291A patent/TWI478908B/zh not_active IP Right Cessation
- 2012-06-28 TW TW105120804A patent/TWI622583B/zh not_active IP Right Cessation
- 2012-06-28 TW TW107102252A patent/TW201837023A/zh unknown
- 2012-06-29 PE PE2013002817A patent/PE20140690A1/es active IP Right Grant
- 2012-06-29 PL PL12735402T patent/PL2726466T3/pl unknown
- 2012-06-29 HU HUE12735402A patent/HUE029398T2/en unknown
- 2012-06-29 CA CA2838223A patent/CA2838223A1/en not_active Abandoned
- 2012-06-29 NZ NZ716245A patent/NZ716245A/en not_active IP Right Cessation
- 2012-06-29 EP EP16169320.5A patent/EP3098218B1/en active Active
- 2012-06-29 WO PCT/US2012/045086 patent/WO2013006485A1/en not_active Ceased
- 2012-06-29 PT PT127354025T patent/PT2726466T/pt unknown
- 2012-06-29 KR KR1020137033295A patent/KR101608927B1/ko not_active Expired - Fee Related
- 2012-06-29 DK DK12735402.5T patent/DK2726466T3/en active
- 2012-06-29 EP EP12735402.5A patent/EP2726466B1/en active Active
- 2012-06-29 KR KR1020167008350A patent/KR20160040734A/ko not_active Withdrawn
- 2012-06-29 SI SI201230579A patent/SI2726466T1/sl unknown
- 2012-06-29 AU AU2012279236A patent/AU2012279236B2/en not_active Ceased
- 2012-06-29 UA UAA201314145A patent/UA115529C2/uk unknown
- 2012-06-29 RS RS20160623A patent/RS55024B1/sr unknown
- 2012-06-29 EP EP16169333.8A patent/EP3088395B1/en active Active
- 2012-06-29 ES ES12735402.5T patent/ES2583415T3/es active Active
- 2012-06-29 EA EA201391639A patent/EA027356B1/ru not_active IP Right Cessation
- 2012-06-29 EP EP16169314.8A patent/EP3101013B1/en active Active
- 2012-06-29 CN CN201280042528.4A patent/CN103857659B/zh not_active Expired - Fee Related
- 2012-06-29 EP EP16169386.6A patent/EP3085696B1/en active Active
- 2012-06-29 PH PH1/2013/502549A patent/PH12013502549B1/en unknown
- 2012-06-29 MX MX2013014846A patent/MX336810B/es active IP Right Grant
- 2012-06-29 ES ES16169386T patent/ES2790633T3/es active Active
- 2012-06-29 EA EA201790417A patent/EA201790417A3/ru unknown
- 2012-06-29 ES ES16169314T patent/ES2842433T3/es active Active
- 2012-06-29 HR HRP20160952TT patent/HRP20160952T1/hr unknown
- 2012-06-29 ES ES16169333T patent/ES2792866T3/es active Active
- 2012-06-29 MD MDA20130095A patent/MD4371C1/ro not_active IP Right Cessation
- 2012-06-29 ES ES16169306T patent/ES2792864T3/es active Active
- 2012-06-29 EP EP16169306.4A patent/EP3085694B1/en active Active
- 2012-06-29 AR ARP120102370A patent/AR086828A1/es unknown
- 2012-06-29 ME MEP-2016-152A patent/ME02546B/me unknown
- 2012-06-29 US US13/538,847 patent/US8586732B2/en active Active
- 2012-06-29 NZ NZ618691A patent/NZ618691A/en not_active IP Right Cessation
- 2012-06-29 BR BR112013032361A patent/BR112013032361A2/pt not_active Application Discontinuation
- 2012-06-29 ES ES16169320T patent/ES2797128T3/es active Active
- 2012-06-29 JP JP2014519190A patent/JP5889407B2/ja not_active Expired - Fee Related
- 2012-06-29 AP AP2013007300A patent/AP2013007300A0/xx unknown
- 2012-06-29 CN CN201611165938.4A patent/CN106995415A/zh active Pending
-
2013
- 2013-03-07 US US13/789,469 patent/US8697863B2/en active Active
- 2013-09-26 US US14/038,646 patent/US9193694B2/en active Active
- 2013-11-29 ZA ZA2013/08981A patent/ZA201308981B/en unknown
- 2013-12-13 CO CO13291981A patent/CO6821960A2/es not_active Application Discontinuation
- 2013-12-13 CR CR20130658A patent/CR20130658A/es unknown
- 2013-12-16 EC ECSP13013083 patent/ECSP13013083A/es unknown
- 2013-12-16 CL CL2013003598A patent/CL2013003598A1/es unknown
- 2013-12-18 IL IL230022A patent/IL230022B/en active IP Right Grant
-
2015
- 2015-10-01 US US14/872,787 patent/US9598435B2/en active Active
- 2015-12-28 JP JP2015255906A patent/JP6273250B2/ja not_active Expired - Fee Related
-
2016
- 2016-05-11 US US15/152,231 patent/US9676760B2/en active Active
- 2016-08-08 SM SM201600271T patent/SMT201600271B/it unknown
- 2016-08-18 CY CY20161100816T patent/CY1117915T1/el unknown
- 2016-12-08 HK HK16113995.0A patent/HK1225724A1/en unknown
- 2016-12-08 HK HK16113997.8A patent/HK1225725A1/en unknown
- 2016-12-08 HK HK16113998.7A patent/HK1225726A1/en unknown
- 2016-12-15 HK HK16114300.8A patent/HK1226061A1/en unknown
- 2016-12-15 HK HK16114299.1A patent/HK1226060A1/en unknown
-
2018
- 2018-01-08 IL IL256779A patent/IL256779A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12060367B2 (en) | Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer | |
| HRP20160952T1 (hr) | Fuzionirani benzoksazepinoni kao modulatori jonskih kanala | |
| US9006263B2 (en) | Compounds and methods for treatment of hypertension | |
| US6472389B1 (en) | Pyrrolo[1,2-b] pyridazine derivatives having sPLA2 inhibitory effect | |
| TW202245779A (zh) | 用於抑制ｒａｓ之組合物及方法 | |
| KR20200116481A (ko) | Gcn2 억제제 및 이의 용도 | |
| US20230227470A1 (en) | Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer | |
| US11407831B2 (en) | Pharmaceutical composition administered in combination with substituted dihydropyrrolopyrazole compound and immunotherapeutic agent | |
| HK1236927A1 (en) | Fused benzoxazepinones as ion channel modulators | |
| HK40039599A (en) | Gcn2 inhibitors and uses thereof |